Founding year:
2011
Employees:
51-500
Website:
Visit website
Expansion:
national
Jobs for Engineers, IT, Physicians & Scientists
AvenCell Europe GmbH
Dresden
Employees: 51-500
Your career at AvenCell Europe
Our Story
After 10 years of private ownership, GEMoaB joined forces with the US-based and leading clinical-stage genome editing company Intellia Therapeutics to develop “off-the-shelf” universal CAR-T cell therapies for immuno-oncology and autoimmune diseases. Financed by the private investment platform Blackstone Life Sciences, the novel CAR-T cell company AvenCell Therapeutics was launched to combine GEMoaB’s world-leading clinical-stage universal CAR-T platforms with Intellia’s allogeneic cell platform and CRISPR cell engineering.
GEMoaB became a daughter company of AvenCell Therapeutics based in Cambridge, Massachusetts and changed its name into AvenCell Europe.
After 10 years of private ownership, GEMoaB joined forces with the US-based and leading clinical-stage genome editing company Intellia Therapeutics to develop “off-the-shelf” universal CAR-T cell therapies for immuno-oncology and autoimmune diseases. Financed by the private investment platform Blackstone Life Sciences, the novel CAR-T cell company AvenCell Therapeutics was launched to combine GEMoaB’s world-leading clinical-stage universal CAR-T platforms with Intellia’s allogeneic cell platform and CRISPR cell engineering.
GEMoaB became a daughter company of AvenCell Therapeutics based in Cambridge, Massachusetts and changed its name into AvenCell Europe.
We offer our employees:
Employee Perks
Incentives & events
Company ticket
Flexible working hours
Beverages
Good transport connection
Employee laptop
Application & Start your career at AvenCell Europe
How to apply
- Online application
Company Details for AvenCell Europe
Your Job With Us: Who We Are Looking For
Location
AvenCell Europe GmbH
Tatzberg 47
01307 Dresden
Germany
